Phase I Study To Evaluate The Toxicity And Feasibility Of Intratumoral Injection Of Alpha-Gal (Beta-galactosidase ) Glycosphingolipids In Patients With Advanced Melanoma

Trial Profile

Phase I Study To Evaluate The Toxicity And Feasibility Of Intratumoral Injection Of Alpha-Gal (Beta-galactosidase ) Glycosphingolipids In Patients With Advanced Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2015

At a glance

  • Drugs AGI 134 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 19 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 22 May 2013 Planned number of patients changed from 24 to 12 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top